Search
Tozinameran
go.drugbank.com/drugs/DB15696ApprovedInvestigational[A225386] Comirnaty was granted a EUA in the UK on December 2, 2020,[L26676] and in Canada on December 9, 2020[L26671] for active immunization against SARS-CoV-2. … FDA on July 13, 2020.
Categories: Complex MixturesMidazolam
go.drugbank.com/drugs/DB00683ApprovedIllicitInvestigational[L45098] In late 2018, the intramuscular preparation was approved by the FDA for the treatment of status epilepticus in adults. … [L45098] In May 2019, the nasal spray of midazolam was approved for the acute treatment of distinctive intermittent, stereotypic seizure episodes in patients 12 years of age and older.
Products: N/a, Midazolam in Sodium ChlorideBesilesomab
go.drugbank.com/drugs/DB13979ApprovedBesilesomab is a mouse monoclonal antibody labelled with the radioactive isotope technetium-99m for determining the location of inflammation/infection in peripheral bone in adults with suspected osteomyelitis … Utilised only as a diagnostic agent, besilesomab is currently approved by the EMEA for marketing and use in various European countries like Italy, France, Germany, Spain, Portugal, Norway, Sweden, the
Nickel sulfate
go.drugbank.com/drugs/DB14180ApprovedNickel sulfate is used in allergenic testing.
Categories: Compounds used in a research, industrial, or household settingrCFP-10
go.drugbank.com/drugs/DB21907ApprovedrCFP-10 is a recombinant culture filtrate protein of _Mycobacterium tuberculosis_ used as an ingredient in the diagnostic agent SIILTIBCY along with [rdESAT-6].[L53638]
Anisotropine methylbromide
go.drugbank.com/drugs/DB00517ApprovedIts use as treatment adjunct in peptic ulcer has been replaced by the use of more effective agents. … action on the bile ducts and gallbladder.
Neratinib
go.drugbank.com/drugs/DB11828ApprovedInvestigationalNeratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. … Neratinib is currently under investigation for use in many other forms of cancer.
Mirdametinib
go.drugbank.com/drugs/DB07101ApprovedInvestigational[L52485] NF1 is an autosomal-dominant genetic condition caused by loss-of-function variants in the _NF1_ tumour suppressor gene,[A265065,A265070] leading to neurofibromin dysfunction and aberrant activation … On February 11, 2025, mirdametinib was approved by the FDA for the treatment of neurofibromatosis type 1 (NF1).
Synonyms: N-(((R)-2,3-DIHYDROXYPROPYL)OXY)-3,4-DIFLUORO-2-((2-FLUORO-4-IODOPHENYL)AMINO)BENZAMIDE N-((2R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2-FLUORO-4-IODOANILINO)BENZAMIDE, (-)-N-(((R)-2,3-DIHYDROXYPROPYL)OXY)-3,4-DIFLUORO-2-((2-FLUORO-4-IODOPHENYL)AMINO)BENZAMIDELetermovir
go.drugbank.com/drugs/DB12070ApprovedInvestigationalLetermovir recieved approval from the FDA on November 8th, 2017 for use in prophylaxis of cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell transplant patients. … [L1021] It is the first of a new class of CMV anti-infectives called DNA terminase complex inhibitors.[A31290] Letermovir has recieved both priority and orphan drug status from the FDA.
Categories: DNA Terminase Complex Inhibitors, Cytomegalovirus DNA Terminase Complex InhibitorPegunigalsidase alfa
go.drugbank.com/drugs/DB14992ApprovedInvestigational[A259347,A259352] In May 2023, the EMA granted marketing authorization to pegunigalsidase alfa in the European Union (EU) for the treatment of adult patients with Fabry disease. … While agalsidase alfa and agalsidase beta enter lysosomes via the mannose-6-phosphate (M6P) receptor, pegunigalsidase alfa carries no M6P on its glycans and does not depend on the M6P receptor during cellular